Related content

Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer

By Beyer D.C.   Thomas T.   Hilbe J.   Swenson V.  

Brachytherapy, Vol. 2, Iss. 2, 2003-06 ,pp. : 77-84

Elsevier

Access to resources Recommend Favorite

Specificity and accuracy of TRUS-measured PSA-density and transition zone-PSA in the diagnosis of prostate cancer

By Michielsen D.P.J.   De Boe V.R.   Braeckman J.G.   Keuppens F.I.  

European Journal of Ultrasound, Vol. 8, Iss. 2, 1998-11 ,pp. : 125-128

Elsevier

Access to resources Recommend Favorite

Broadsheet number 42: Prostate specific antigen update

By Sikaris K.A.   Meerkin M.   Guerin M.D.  

Pathology, Vol. 30, Iss. 1, 1998-02 ,pp. : 17-23

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Differentiation of prostate cancer from benign prostate hypertrophy using dual-echo dynamic contrast MR imaging

By Muramoto S.   Uematsu H.   Kimura H.   Ishimori Y.   Sadato N.   Oyama N.   Matsuda T.   Kawamura Y.   Yonekura Y.   Okada K.   Itoh H.  

European Journal of Radiology, Vol. 44, Iss. 1, 2002-10 ,pp. : 52-58

Elsevier

Access to resources Recommend Favorite

Preclinical evaluation of BAY 1075553, a novel ¹⁸F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer

By Lesche Ralf   Kettschau Georg   Gromov Alexey   Böhnke Niels   Borkowski Sandra   Mönning Ursula   Hegele-Hartung Christa   Döhr Olaf   Dinkelborg Ludger   Graham Keith  

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, Iss. 1, 2014-01 ,pp. : 89-101

Springer Publishing Company

Access to resources Recommend Favorite